BHC
Bausch Health Companies Inc.
BHC trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over BHC overall, supported by stronger fundamentals and lower modeled downside.
BHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Strong | |
| Weak |
BHC's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BHC PE Valuation
BHC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect BHC's earnings, revenue and profitability to hold roughly steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BHC on the outlook, with more favorable earnings and revenue expectations.
BHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.30 | — |
| Q3 2026 | -$2.29 | -339% |
| Q2 2026 | -$2.96 | -1284% |
| Q1 2026 | -$3.24 | -$3.12 |
| Q4 2025 | $0.42 | +$0.55 |
| Q3 2025 | $0.96 | +$1.44 |
| Q2 2025 | $0.25 | +$1.53 |
| Q1 2025 | -$0.12 | +$1.12 |
| Q4 2024 | -$0.13 | +$1.49 |
BHC has swung to a loss: it lost $2.29 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BHC on earnings quality, reporting a profit while its opponent remains loss making.
BHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +9.7% |
| Q2 2026 | $2.9B | +13% |
| Q1 2026 | $2.5B | +12% |
| Q4 2025 | $2.8B | +9.3% |
| Q3 2025 | $2.7B | +6.8% |
| Q2 2025 | $2.5B | +5.3% |
| Q1 2025 | $2.3B | +4.9% |
| Q4 2024 | $2.6B | +6.3% |
BHC's revenue has grown year over year for 15 quarters in a row: $2.9B last quarter, up 9.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 33% | +10 points |
| Q2 2026 | 26% | +8.4 points |
| Q1 2026 | -38% | -50 points |
| Q4 2025 | 17% | -4.9 points |
| Q3 2025 | 23% | +10 points |
| Q2 2025 | 18% | +1.4 points |
| Q1 2025 | 12% | -0.8 points |
| Q4 2024 | 22% | +6.8 points |
BHC's operating margin was 33% last quarter, up 10 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BHC on profitability, with a higher operating margin.
BHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $748M | +138% |
| Q2 2026 | $593M | +212% |
| Q1 2026 | $121M | +26% |
| Q4 2025 | $403M | -19% |
| Q3 2025 | $314M | -6% |
| Q2 2025 | $190M | -37% |
| Q1 2025 | $96M | -26% |
| Q4 2024 | $495M | +70% |
BHC generated $1.9B in free cash flow over the past year, up 70% from the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BHC on cash flow, with more consistent year-over-year improvement.
BHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.6M shares |
| 1 year | +1.4% | +5.2M shares |
| 3 years | +4.2% | +15.3M shares |
| 5 years | +4.6% | +16.7M shares |
| Available history | +8.1% | +28.6M shares |
BHC has 381M diluted shares, up 1.4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.6x | High |
| Q2 2026 | 9.2x | High |
| Q1 2026 | 10.9x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 7.1x | High |
| Q1 2025 | 7.3x | High |
| Q4 2024 | 7.3x | High |
BHC's net debt is about 7.6 years of its operating earnings (EBITDA), up from 6.3 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BHC on leverage, with a lower net debt burden relative to earnings.
BHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.2 | Overbought |
| Stochastic | 78.2 | Neutral |
BHC's weekly RSI is 71 (overbought) and its Stochastic is 78 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BHC PE vs Healthcare Sector
| Metric | BHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BHC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.86 | 20% above |
| 20 week MA | $6.22 | 33% above |
| 50 week MA | $6.00 | 38% above |
| 100 week MA | $6.22 | 33% above |
| 200 week MA | $7.03 | 17% above |
BHC has climbed back above all five of its weekly moving averages, and it's now 17% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
BHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.7 | $20.3 | -32% |
| 2021 | $20.3 | $28.0 | +38% |
| 2022 | $28.0 | $6.33 | -77% |
| 2023 | $6.33 | $8.02 | +27% |
| 2024 | $8.02 | $7.65 | -4.6% |
| 2025 | $7.65 | $7.20 | -5.9% |
| 2026 YTD | $7.20 | $8.25 | +15% |
BHC has finished lower in four of the last six years. It's up 15% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BHC on returns for 2026, with the stronger performance.